Navigation Links
July 11 Nomination Deadline Nears for Blue Cross Blue Shield of Michigan Annual Claude Pepper Community Service Awards
Date:6/20/2008

Awards Honor Outstanding Senior Citizen Advocates

DETROIT, June 20 /PRNewswire/ -- There is still time before the July 11 deadline to nominate deserving Michigan senior citizen advocates for the 18th annual Claude Pepper Awards sponsored by Blue Cross Blue Shield of Michigan.

The awards are presented to two individuals whose professional or volunteer efforts have significantly improved the lives of Michigan seniors, particularly those whose access to health care services may be hindered by physical, mental, financial or geographical limitations. The awards are named for the late Florida Sen. Claude Pepper, one of the principal sponsors of the Older Americans Act of 1965 and a major force in strengthening Social Security and Medicare.

Nomination forms and additional information are available online at bcbsm.com/awards. Forms also can be obtained by phoning 800-733-BLUE (2583) or by writing to Blue Cross Blue Shield of Michigan Community Service Awards, Mail Code 0620, 600 E. Lafayette Blvd., Detroit, MI 48226.

The Blue Cross Blue Shield of Michigan Senior Advisory Council Education Committee will review all Claude Pepper Award nominations. Winners each receive a $1,000 donation for their respective nonprofit organizations. Runners-up will receive certificates of merit.

The Claude Pepper Awards will be presented Friday, Sept.19 in Traverse City during the Senior Advisory Council annual conference on healthy aging. To register, call 800-733-BLUE (2583).

Blue Cross Blue Shield of Michigan, a nonprofit organization, provides and administers health benefits to 4.7 million members residing in Michigan in addition to members of Michigan-headquartered groups who reside outside the state. The company offers a broad variety of plans including: Traditional Blue Cross Blue Shield; Blue Preferred, Community Blue and Healthy Blue Incentives PPOs; Blue Care Network HMO; BCN Healthy Blue Living; Flexible Blue plans compatible
'/>"/>

SOURCE Blue Cross Blue Shield of Michigan
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Courage Center Extends Nomination Deadline for 2008 Phillips Awards to July 3
2. Nominations Accepted for 2008 Champions of Health Awards
3. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
4. Blue Cross Blue Shield of Michigan Seeking Nominations for Outstanding Senior Advocates
5. Wanted: Illinois Family Physician of the Year Nominations
6. Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27
7. Cadient Group Receives Multiple Nominations for 2008 DTC National Advertising Awards
8. Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Board at the 2008 Annual Meeting
9. Cherokee Inspired Comfort Awards Program Call for Nominations
10. OSHA Seeking Nominations for National Advisory Committee on Occupational Safety and Health
11. Nanotech Briefs Announces Call for Nominations for the Fourth Annual Nano 50(TM) Awards
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Finally a Health Care Option for Small Businesses 50925 1Finally a Health Care Option for Small Businesses 50925 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 12009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 1Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 2Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 4
Other Medicine Technology:Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 2Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 3Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 4Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 5Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10